Andere Sprachen Pharma Mar, S.A.

Aktien

A2P9YT

ES0169501022

PHM

Markt geschlossen - BME Andere Börsenplätze 17:35:28 18.04.2024			% 5 Tage	% 1. Jan.
26,62 ^EUR	+0,38 %		-3,83 %	-35,20 %

29.02.	Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024
28.02.	Pharma Mar, S.A. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
OPINIONES DE LOS ANALISTAS DEL DÍA : Adyen, Endesa, Viscofan, Iberdrola, Repsol, Pharma Mar, NH Hotel, Nemetschek, Société Générale...	09.02.
Bolsa de Madrid: Caramba, ¡falló otra vez!	09.02.
PharmaMar presents new results of lurbinectedin at the ASCO Symposium on Genitourinary Cancers	30.01.
EN DIRECTO DESDE LOS MERCADOS: Pharma Mar, Repsol, Cie Automotive, Alphabet, UBS, Acciona, Richemont, Covestro, Apple...	19.12.
Pharma Mar's Sylentis Meets Primary Endpoint for Dry Eye Disease Medication	18.12.
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	12.12.
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Macau, China	05.12.
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	04.12.
Pharma Mar's Partner Wins Commercialization Approval for Zepzelca in Peru	07.11.
PharmaMar receives a payment of 10 million dollars from Janssen as a commercial milestone	07.11.
PharmaMar Gets $10 Million Milestone Payment from Janssen Under Yondelis Licensing Deal	06.11.
EN DIRECTO DESDE LOS MERCADOS: Pharma Mar, Sacyr, LVMH, Iberdrola, Dufry, Berkshire Hathaway, Ryanair, Telecom Italia	06.11.
Pharma Mar, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	26.10.23
PharmaMar presents new data on lurbinectedin for small cell lung cancer at ESMO 2023	19.10.23
OPINIONES DE LOS ANALISTAS DEL DÍA : Amadeus, Sacyr, Nokia, Telefónica, Pharma Mar, Novo Nordisk, Rheinmetall, Prosegur, Almirall, Vodafone...	11.10.23
PharmaMar increased investment in R&D in oncology by 23% in 2022	25.09.23
PharmaMar licenses lurbinectedin to Key Oncologics for marketing and distribution in Africa	13.09.23
PharmaMar will present new data on lurbinectedin at the IASLC 2023 World Lung Cancer Congress	11.09.23
Pharma Mar, S.A. commences an Equity Buyback Plan, under the authorization approved on May 31, 2023.	06.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Pharma Mar, S.A.

Aktien

A2P9YT

ES0169501022

PHM

Andere Sprachen

Filter